8-K: Plus Therapeutics Averts Nasdaq Delisting

Plus Therapeutics, Inc. received conditional approval for continued Nasdaq listing after addressing non-compliance with equity and bid price requirements.

Summary

• Plus Therapeutics, Inc. (PSTV) was notified on June 3, 2025, of non-compliance with Nasdaq Listing Rule 5550(b)(1) due to failing to maintain a minimum of $2.5 million in stockholders equity.
• The company reported a stockholders equity deficit of ($23,641,000) in its Quarterly Report on Form 10-Q for the period ended March 31, 2025.
• As a result of the non-compliance, Nasdaq Staff determined to delist the company's securities.
• The company timely appealed the decision, and a hearing took place on July 15, 2025.
• On July 22, 2025, the Nasdaq Hearings Panel issued a decision granting the company's request for continued listing, subject to specific conditions.
• The conditions require the company to demonstrate compliance with the Minimum Stockholders Equity Requirement by August 14, 2025, and achieve a closing bid price of $1.00 or more for 10 consecutive business days on or before September 8, 2025.

Sentiment

Score: 3

Explanation: The company avoided immediate delisting, which is a positive, but it remains in a precarious financial position with a significant equity deficit and a low stock price, facing strict deadlines to regain compliance. The underlying financial health is poor.

Positives

• The Nasdaq Hearings Panel granted the company's request for continued listing, avoiding immediate delisting.
• The company has a clear path and specific deadlines to regain full compliance with Nasdaq listing rules.

Negatives

• The company was non-compliant with Nasdaq's minimum stockholders equity requirement, reporting a deficit of ($23,641,000) as of March 31, 2025.
• The company must achieve a closing bid price of $1.00 or more for 10 consecutive business days by September 8, 2025, which indicates current share price weakness.
• Failure to meet the conditions by the specified deadlines will likely result in delisting.

Risks

• Risk of delisting from Nasdaq if the company fails to demonstrate compliance with the $2.5 million Minimum Stockholders Equity Requirement by August 14, 2025.
• Risk of delisting if the company's common stock closing bid price does not meet or exceed $1.00 for a minimum of 10 consecutive business days on or before September 8, 2025.
• The significant stockholders equity deficit of ($23,641,000) as of March 31, 2025, indicates ongoing financial challenges and potential need for further capital.

Future Outlook

The company has been granted a conditional extension to regain compliance with Nasdaq listing standards, requiring it to demonstrate improved financial health and stock performance by specific deadlines in August and September 2025.

Industry Context

NA

Stakeholder Impact

• Shareholders: Face significant risk of delisting if compliance conditions are not met, potential dilution if a capital raise occurs, and current share price weakness.
• Employees: Potential uncertainty regarding the company's long-term viability if delisting occurs.
• Creditors: May face increased risk due to the company's significant equity deficit.

Next Steps

• Demonstrate compliance with the $2.5 million Minimum Stockholders Equity Requirement by August 14, 2025, by filing a public disclosure detailing transactions and equity status.
• Achieve a closing bid price of $1.00 or more for a minimum of 10 consecutive business days on or before September 8, 2025.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a substantial stockholders' equity deficit of over $23 million and a stock price below the Nasdaq minimum. While a conditional reprieve from delisting was granted, the stringent deadlines for regaining compliance with both equity and bid price requirements present significant execution risk. Failure to meet these conditions will result in delisting, severely impairing liquidity and investor confidence. The current financial state suggests a high probability of further value erosion, making it a high-risk investment with limited upside potential given the immediate challenges.

Keywords

Plus Therapeutics, PSTV, Nasdaq, Delisting, Stockholders Equity, Bid Price, Compliance, 8-K, SEC Filing